Skip to main content

Table 2 Response rates & subgroup analysis

From: Bendamustine in patients with relapsed or refractory multiple myeloma

    Subgroups dosage   Subgroups therapy mode  
    80-100 mg/m 2 120-150 mg/m 2   Monotherapy + Steroids  
n = 39    n = 21 n = 18 p n = 12 n = 27 p
PR 14 (1 vgPR) 36% 7 33% 7 38% 0.8 3 25% 11 40% 0.5
MR 7 18% 4 19% 3 17% 1.0 2 17% 5 19% 1.0
SD 10 26% 7 33% 3 17% 0.3 5 42% 5 19% 0.2
PD 8 20% 3 15% 5 28% 0.4 2 17% 6 22% 1.0
  1. vgPR very good partial remission; PR partial remission; MR Minor remission; SD stable disease; PD progressive disease